Who Should Monitor for Gastroparesis While Taking Ozempic?

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Education to Occupational Exposure Risk

If you're taking Ozempic and experiencing persistent nausea, vomiting, or abdominal pain, you may wonder whether these are normal side effects or signs of gastroparesis. Distinguishing symptoms from a formal diagnosis is crucial for proper management. Building on decades of pharmacovigilance research, this page explains the FAERS data on Ozempic-associated gastroparesis and outlines who may need closer monitoring.

Clinical Presentation and Diagnosis of Gastroparesis

Gastroparesis, a condition characterized by delayed gastric emptying without mechanical obstruction, has emerged as a serious concern in patients using Ozempic. This section examines the clinical presentation and diagnosis of gastroparesis, the pharmacology of Ozempic, mechanistic pathways linking the drug to gastroparesis, adequacy of warnings, settlement-related considerations, and the timeline between exposure and documented harm. Gastroparesis presents with symptoms such as nausea, vomiting, early satiety, postprandial fullness, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. The condition can lead to malnutrition, dehydration, and significant impairment in quality of life. In the context of Ozempic use, these symptoms may overlap with common gastrointestinal adverse reactions reported in clinical trials. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: placebo 15.3%, Ozempic 0.5 mg 32.7%, and Ozempic 1 mg 36.4% (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal side effects, which may include symptoms mimicking or indicating gastroparesis.

Pharmacology and Mechanistic Pathways Linking Ozempic to Gastroparesis

The pharmacology of Ozempic involves activation of GLP-1 receptors, which slows gastric emptying as part of its mechanism to regulate postprandial glucose levels. This effect is intended but can become pathological when excessive or prolonged, leading to gastroparesis. Mechanistic pathways linking Ozempic to gastroparesis include delayed gastric emptying due to GLP-1 receptor activation on gastric smooth muscle and enteric neurons, which reduces antral contractions and increases pyloric tone. Additionally, Ozempic may affect vagal nerve signaling, further impairing gastric motility. While the drug label does not explicitly list gastroparesis as an adverse reaction, it does document gastrointestinal adverse reactions with frequencies below 5%, including dyspepsia (placebo 1.9%, Ozempic 0.5 mg 3.5%, Ozempic 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These conditions may be precursors or components of gastroparesis, but the label does not specifically warn about gastroparesis as a distinct risk.

Adequacy of Warnings and Settlement Considerations

The adequacy of warnings regarding Ozempic and gastroparesis is a critical risk anchor. The label includes warnings about serious hypersensitivity reactions such as anaphylaxis and angioedema (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), but does not contain a specific warning for gastroparesis. This omission may be significant for patients who develop severe gastric symptoms that persist beyond dose escalation. The lack of explicit warning could affect informed consent and patient awareness of potential long-term gastric complications. For affected patients, settlement-related considerations may include the need to demonstrate that the drug caused gastroparesis, that warnings were inadequate, and that harm resulted. Evidence from clinical trials showing higher rates of gastrointestinal adverse reactions with Ozempic compared to placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166) may support causation, but establishing a direct link to gastroparesis specifically may require additional clinical data or expert testimony. The timeline between exposure and documented harm is another important factor. In clinical trials, gastrointestinal adverse reactions occurred most frequently during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), suggesting that symptoms may appear early in treatment. However, gastroparesis can develop or become apparent after prolonged use, and the label does not provide specific data on the duration of exposure leading to gastroparesis. Patients who discontinue Ozempic due to gastrointestinal adverse reactions may experience resolution of symptoms, but those with persistent gastroparesis may require ongoing medical management. The discontinuation rates due to gastrointestinal adverse reactions (3.1% for 0.5 mg and 3.8% for 1 mg) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166) indicate that a subset of patients experiences significant harm, which could form the basis for legal claims.

Summary of Evidence and Risk Context

In summary, Ozempic is associated with a higher incidence of gastrointestinal adverse reactions compared to placebo, and these reactions can include symptoms consistent with gastroparesis. The drug's mechanism of action, which slows gastric emptying, provides a plausible pathway for the development of gastroparesis. However, the label does not specifically warn about gastroparesis, which may be a deficiency in risk communication. For patients pursuing settlement, key considerations include the strength of evidence linking Ozempic to gastroparesis, the adequacy of warnings, and the timeline of symptom onset relative to drug exposure. Legal claims may rely on clinical trial data showing increased gastrointestinal adverse reactions and discontinuation rates, as well as expert medical opinion on causation. References (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166)

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Ozempic and gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying as part of its mechanism. This can become pathological, leading to gastroparesis. Clinical trials show higher rates of gastrointestinal adverse reactions with Ozempic compared to placebo, including symptoms consistent with gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Does the Ozempic label warn about gastroparesis?

No, the label does not specifically warn about gastroparesis. It lists gastrointestinal adverse reactions such as dyspepsia, gastritis, and GERD, but does not mention gastroparesis as a distinct risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

What are the settlement criteria for Ozempic gastroparesis lawsuits?

Settlement criteria typically require documented Ozempic exposure, a confirmed gastroparesis diagnosis, evidence that the drug caused the condition, and that warnings were inadequate. Clinical trial data showing increased gastrointestinal adverse reactions and discontinuation rates may support claims (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.